FIA
TNXP icon

FNY Investment Advisers’s Tonix Pharmaceuticals TNXP Stock Holding History

FNY Investment Advisers’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,100
Closed -$19K – 1187
2025
Q1 		$19K Buy
+1,100
New +$22.3K 0.01% 411

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SPS
Susquehanna Portfolio Strategies Bala Cynwyd, Pennsylvania $6.73B AUM 45.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's TNXP Position: Q2 2025 in Review

FNY Investment Advisers sold out of Tonix Pharmaceuticals (TNXP) in Q2 2025, closing a stake of 1,100 shares — an estimated $19K sold.

FNY Investment Advisers first reported a position in TNXP in Q1 2025 and held it in 1 quarter. The position peaked at $19K in Q1 2025. 47 funds tracked by Wall St. Rank hold TNXP as of Q2 2025.

  • FNY Investment Advisers reported no remaining Tonix Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 1,100 Tonix Pharmaceuticals shares in Q2 2025, an estimated $19K.
  • FNY Investment Advisers first reported a position in Tonix Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • FNY Investment Advisers's Tonix Pharmaceuticals position peaked at $19K in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2025.

Based on FNY Investment Advisers's 13F filing for Q2 2025, filed 30 Jul 2025.